Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With rBet v1-FV Compared to Placebo in Birch Pollen-Allergic Patients With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis

NCT01490411 is registered in ClinicalTrials.gov with Allergopharma GmbH & Co. KG as lead sponsor.

NCT NCT01490411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01490411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With rBet v1-FV Compared to Placebo in Birch Pollen-Allergic Patients With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis
Lead sponsor
Allergopharma GmbH & Co. KG
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
September 30, 2011
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinoconjunctivitis